Amicus Therapeutics' low P/S ratio suggests investor worries...
Amicus Therapeutics' low P/S ratio suggests investor worries about weak revenue growth compared to the booming Biotech sector, potentially hindering significant share price gains soon.
Lacklustre Performance Is Driving Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Low P/S
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment
Moomoo AI Official Account
Your AI assistant for discovering investment opportunities.
4478Followers
0Following
9822Visitors
Follow